ARMO BioSciences, Inc. (NASDAQ:ARMO) issued its earnings results on Monday, April, 2nd. The company reported ($9.62) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.45) by $9.17. View ARMO BioSciences' earnings history.

Köp aktien Armo Biosciences, Inc. (ARMO). Hos Nordnet kan du handla från 0 kr i courtage. Klicka här för att följa aktiekursen i realtid

Exploiting the Body’s Immune System to Treat a Broad Range of Diseases. ARMO Biosciences, a wholly owned subsidiary of Eli Lilly and Company. 2018-05-14 2018-05-10 2018-05-10 2018-06-22 As a founder and Senior Director of Technical Operations at ARMO, John lead the manufacturing and pre-clinical research teams. John is currently the Director of Immunoncology R&D at Medimmune LLC and is the author of 27 peer reviewed manuscripts and 18 granted or pending patents.

Armo biosciences founder

ARMO is a clinical stage company developing immunotherapy-based drugs for the treatment of a variety of cancer. ARMO BioSciences stock price prediction is an act of determining the future value of ARMO BioSciences shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation.The successful prediction of ARMO BioSciences stock future price could yield a significant profit. 2013-11-25 ARMO BioSciences, Inc. (Name of Subject Company) ARMO BioSciences, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securities) 04225U104 (CUSIP Number of Class of Securities) Peter Van Vlasselaer, Ph.D. Chief Executive Officer . ARMO BioSciences, Inc. 575 Chesapeake Drive . Redwood City, CA 94063 2017-04-27 ARMO 10-Year Price Chart: Below is a graph showing closing prices of ARMO BioSciences Inc (ARMO) for the past 10 years.

Senior Scientist.

ARMO Biosciences is a biotechnology company that develops immune modulatory biologic therapeutics. The company is based in Redwood City, California.

See the full leadership team at Craft. Founder, President & Chief Executive Officer: Peter Van Vlasselaer Ph.D: Co-Founder, Chief Executive Officer, President & Board Member: Gail Brown MD: Chief Marketing Officer: Scott Ogg Ph.D: Vice President, Corporate Development & Operations: Russell … 2014-05-29 MORE. Company.

ARMO BioSciences General Information Description. Operator of an immuno-oncology company that is developing a pipeline of products that activate the immune system of cancer patients to recognize and eradicate tumors.

Targenics. Co-Founder. Nov-2009 to Oct-2010. Merck. Senior Scientist. Jun-2005 to Nov-2009.

It focuses on developing immunotherapies for the treatment of cancer, cardiovascular disease, fibrosis and inflammation. The Company's platform molecule AM0010 is a pegylated form of recombinant human IL-10, which has immune stimulating IDEAYA Biosciences Announces Agenda for Inaugural Synthetic Lethality Investor Day on Tuesday, April 20, 2021 April 19, 2021 IDEAYA Reports Darovasertib (IDE196) Monotherapy Overall Survival Data and Observes Early Partial Responses in Binimetinib Combination in Metastatic Uveal Melanoma Mr. Jacobs is President and Chief Executive Officer for Harmony Biosciences. He joined Harmony from Teva Pharmaceuticals, where he held leadership roles as Senior Vice President and General Manager of the Respiratory Business Unit, Senior Vice President of Commercial Operations in North America and General Manager of Teva in Canada.
Hay day priser

The company reported ($9.62) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.45) by $9.17.

See the full leadership team at Craft. ARMO BioSciences was founded in 2013. Who are ARMO BioSciences key executives? ARMO BioSciences's key executives are Peter Van Vlasselaer, Herb Cross and Joseph Leveque.
Jobs sweden english speaking

Prior to joining Artios, Niall was a co-founder and Chief Operating Officer at In the past, he was a Board Director at Armo Biosciences, Tobira Therapeutics,

He founded Magic Earth, LLC. in 2000, and as Chairman and CEO, achieved He then founded Targenics, later merged with ARMO BioSciences (now a Director. D r.